Wake Forest University Health Sciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).
Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.
Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.
Top-decile sponsor footprint
Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,140 total, page 9 of 23
Psychometric Properties of the SMART Feeding Tool
NCT05729828
Radiation Therapy on Pelvic Floor Disorders in Women
NCT04623515
Integrated Intervention for Caregivers--Pilot RCT
NCT03487627
Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
NCT04632641
Muscadine Grape Extract to Improve Fatigue
NCT04495751
Rosacea and Ivermectin
NCT04275999
LOVE Trial: Limits On Vaginal Intercourse After Mid-urEthral Sling
NCT04680897
Exercise as Adjunctive Treatment for Refractory Epilepsy
NCT04607317
Preop COVID Testing Patterns
NCT04838119
Wake Forest Post-ICU Telehealth (WFIT) Program
NCT04576065
User Experience of the OSR M-1
NCT04733677
Cancer Within a Pandemic: A Telemental Health Intervention
NCT04659993
SMS System for Patients With Uncontrolled Hypertension
NCT03596242
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
NCT04648696
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
NCT04454489
PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
NCT04540887
Pain Response Evaluation of a Combined Intervention to Cope Effectively
NCT04395001
Use of a Digitally Enabled App With Clinical Team Interface in the Management of Depression
NCT04891224
Hidradenitis Suppurativa Wound Care
NCT04354012
Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation
NCT04727827
Application to Improve Patient Engagement and Decrease Postoperative Opioid Consumption in Patients for Colorectal Surgery
NCT06350916
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
NCT03868943
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
NCT04327700
Telephone-Based Intervention to Treat Depression and Anxiety in Hispanic Cancer Survivors
NCT04430335
RUral dispaRities in prehospitAL STEMI
NCT04381260
Fractional Ablative Laser Treatment for Skin Grafts
NCT04176705
A Device to Determine Return of Sensation From Spinal Block
NCT04553913
Pharmacogenomic Testing to Personalize Supportive Oncology
NCT04500301
Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only
NCT04527523
Effect of Fish Oil on Athlete's Executive Function
NCT04570995
Increased Monitoring of Physical Activity and Calories With Technology
NCT03961061
Generate a Pharmacodynamic Model of Oxytocin for Peripheral Analgesic Effects
NCT04431206
Impact Of Nurse Navigation Program on Outcomes in Patients With GI Cancers
NCT04602611
Promoting Altruism to Enhance Vaccine Acceptance
NCT04568590
Extubation Criteria in Patients Greater Than 59 Years of Age
NCT04596735
Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients
NCT04398199
COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry
NCT04559009
ABTHERA ADVANCE™ Use Without Wittman Patch
NCT04986943
A Pilot Trial of Continuous Portable Postoperative Hemodynamic And Saturation Monitoring On Hospital Wards
NCT04574908
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
NCT03935282
CONNECTing Head and Neck Caregivers to Supportive Care Resources
NCT03875885
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma
NCT04217317
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
NCT04356352
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
NCT04337203
Dance and Diabetes/Prediabetes Self-Management
NCT04427982
COVID-19 IgG Formation in Physicians at ALGH and Their Household Members
NCT04540484
Effect of Theta Burst Stimulation on Alcohol Cue Reactivity
NCT04223154
Incentives to Decrease Opioid Use - Pilot
NCT04235582
QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt
NCT04159571
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
NCT04037527
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 96 |
| Phase 2 | 143 |
| Phase 3 | 31 |
| Phase 4 | 80 |
Therapeutic Areas
What is open in the Wake Forest University Health Sciences pipeline
174 recruiting of 1,140 indexed (15% open); 724 completed (64%).
Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Wake Forest University Health Sciences: open-pipeline peers nationwide
Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,140 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- NYU Langone Health · 1,164 trials · 17% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
- University of Florida · 1,106 trials · 15% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Baylor University · 15% recruiting · 33 trials
- Cornell University · 15% recruiting · 66 trials
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
Related
What to do with this Wake Forest University Health Sciences page
1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.
- 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.